| | | Peak VO2 improvement
| Peak VO2 no improvement
| |
| | Men, (%) | 29 (90.6) | 15 (83.3) | 0.446 | | Age (years), mean ± SD | 55.6 ± 9.0 | 58.2 ± 7.7 | 0.308 | | BMI (kg × m−2), mean ± SD | 28.1 ± 3.5 | 29.9 ± 4.1 | 0.101 | | Ischaemic aetiology of HF, (%) | 26 (81.3) | 16 (88.9) | 0.479 | | Myocardial infarction, (%) | 25 (78.1) | 13 (72.2) | 0.639 | | Diabetes, (%) | 7 (21.9) | 7 (38.9) | 0.198 | | Dyslipidaemia, (%) | 24 (75.0) | 15 (83.3) | 0.495 | | Hypertension, (%) | 14 (43.8) | 12 (66.7) | 0.120 | | ACE inhibitor, (%) | 28 (87.5) | 18 (100.0) | 0.118 | | Angiotensin receptor blocker, (%) | 4 (12.5) | 2 (11.1) | 0.884 | | Beta-blocker, (%) | 32 (100.0) | 32 (100.0) | — | | Loop diuretic, (%) | 23 (71.9) | 17 (94.4) | 0.055 | | Spironolactone, (%) | 31 (96.9) | 16 (89.9) | 0.254 | | Aspirin, (%) | 28 (87.5) | 15 (83.3) | 0.684 | | Statin, (%) | 29 (90.6) | 17 (94.4) | 0.632 | | NYHA class before CR, mean ± SD | 2.31 ± 0.47 | 2.50 ± 0.51 | 0.200 | | NYHA class after CR, mean ± SD | 2.00 ± 0.44 | 2.17 ± 0.62 | 0.273 | | LVEF before CR (%), mean ± SD | 30.6 ± 7.4 | 28.8 ± 7.9 | 0.426 | | LVEF after CR (%), mean ± SD | 32.0 ± 7.5 | 29.0 ± 7.9 | 0.187 | | LVEF change after CR (%), mean ± SD | 1.4 ± 3.4 | 0.2 ± 1.8 | 0.220 | | 6-MWT distance before CR (m), mean ± SD | 417.9 ± 103.5 | 417.7 ± 107.1 | 0.993 | | 6-MWT distance after CR (m), mean ± SD | 481.5 ± 90.1 | 442.8 ± 110.0 | 0.184 | | 6-MWT change after CR (m), mean ± SD | 63.6 ± 69.8 | 33.6 ± 47.3 | 0.054 | | TFC before CR (kOhm−1), mean ± SD | 28.4 ± 5.5 | 25.3 ± 4.0 | 0.039 | | TFC after CR (kOhm−1), mean ± SD | 25.7 ± 4.1 | 25.5 ± 3.4 | 0.850 | | TFC change after CR (kOhm−1), mean ± SD | 2.7 ± 3.6 | 0.2 ± 4.1 | 0.012 |
|
|
ACE: angiotensin-converting enzyme, BMI: body mass index, CR: cardiac rehabilitation, LVEF: left ventricular ejection fraction, ns: nonsignificant, NYHA: New York Heart Association, peak VO2: peak oxygen consumption, TFC: thoracic fluid content.
|
